Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
Gilead acquired magrolimab as part of its $4.9 billion acquisition of Forty Seven back in 2020.
Someone should have told them they could have had Faron for $1 billion back then .
If Bexmab data continues as it has , maybe we can command a $4.9 billion price tag .
Approx £62 a share ( a 22 bagger from here ) . That would be nice lol
It will be refreshing to have a drug like Bex out on the market , that not only does what people want , but also doesn't come a with a 10ft long list of side effects and hazardous consequences .
Some update due shortly I reckon .
I guess the price tag goes up the further you can stretch it down the clinical trials .
The Bexmab data has been a massive bonus for them - proving what Bex can do in combi settings.
And if Bexmab gets some kind of accelerated approval for the AML/MDS market - then they have their foot in the door .
But its taken many years for them to get Bex into a proper package to actually sell/partner with .
Dosing/soluble Clever1/biomarkers/manufacturing/ diagnostics have all had to have been sorted .
Luckily , they've now done that , and now investors can look forward to reaping the rewards .
So making it this far and still being 100% wholly owned is big .
Always a hard one to know when to take profit .
This one has accelerated very quickly for me .
Added today , but happily still showing a healthy profit .
Not sold anything , and I'm still reading up on the company as best I can .
The amount I have in here won't keep me awake at night - and I'm not a very good trader , so will see where this runs .
Sometimes , being lazy and leaving your funds in the stock can be the most profitable way to proceed .
Happened with NCYT ,GGP and EUA for me . Ok , they all peaked and took a dive eventually , but a lot further down the road than many predicted .
At Mcap 50m , we haven't entered the hype zone yet , so happy to see the swings , add when I can , and see what Chris does when he takes the helm .
Https://wsw.com/webcast/canaccord89/farn.l/2742223
Nice little update - Markku and MLF are in US in person .
No new data - but from the talk they are having very busy ongoing talks with potential partners at the moment ( as always lol) , but highlighted how Bex is wholly owned , opening new sites shortly in US ( Yale UFC and Fred Hutch) .
Orphan Status has been applied for and expect FDA response in next couple of weeks .
ASH abstact is next goal - new patient efficacy data will be presented by then also , as more patients are on the study already .
When asked about who else is working on Clever1 - Marku says that we have no direct competitors . Well protected by patents until 2037 , and although they are the ' new kids on the block ' , they are expanding in US .
Looking to be Nasdaq ready - as US and hence the Boston office is very important for the future .
So just a quick chat really - but you get the impression that they will be having plenty of meetings .
Mcap is still around £50m .
Having followed pharma shares for years ,progress can be solid , but glacial in speed .
Then all of a sudden you get massive movements that no chart could predict .
I think if something positive is coming , the size of the company at present could change dramatically .
Its just an automated simple system - doesn't really tell a true story as spreads can send it off course so it isn't worth looking at really . If you are getting live quotes at the same time then you can get better idea , but many big ones are delayed so you never really know what time they happened.
Either way , it's looking good here . Added again last week .
Been reading up about this new CEO . Sure does instill alot of confidence as to where this company may be heading .
I managed to watch it this morning on youtube .
He gets better every time - so much achieved in a small space of time .
Alos noted that he had a slide for those new Rio farm in tenements and how his geologists were very pleased to be out there .
Its been rising on almost zero volume sometimes . Not much float sloshing about , so as order come in , they just have to raise the price to get them filled is one guess .
As its not a trading share , those who own stock aren't going to be selling big amounts now for £3 , after waiting years for some kind of commercial deal just around the corner .
The Helsinki exchange has suffered along with US Markets by association due to the credit downgrade , but Faron gets a mention here as one of the risers despite the market conditions .
https://www-arvopaperi-fi.translate.goog/uutiset/helsingin-porssin-lasku-jatkuu-revenio-syoksyy-tulosvaroituksen-saattelemana/c1da540c-93ae-4542-a5db-94a85ff63c25?_x_tr_sl=fi&_x_tr_tl=en&_x_tr_hl=en&_x_tr_pto=sc
and another article - from the last RNS news
https://yle-fi.translate.goog/a/74-20041630?_x_tr_sl=fi&_x_tr_tl=en&_x_tr_hl=en&_x_tr_pto=sc
Its the interest over there that is starting to spread .
Imagine if we got a piece in a mainstream national news outlet over here . The herd , who have yet to even poke their nose over the fence yet , would arrive en masse .
He's a great enthusiastic guy . Not everyones cup of tea but I like him , and he does his best .
Yes there is risk , but he's right about the new big hitters coming in just in time to reap the rewards .
I doubled my holding on Friday .
New patent just out today -
https://patents.justia.com/patent/20230235046
Good to know this is all in hand - commercial manufacturing design nailed on .
No good having a product if it won't ship or store in stable state .
Stable storage formula for Bex for 3 months if stored at 2-8 degrees - although they have seen it stable after 2 years ( and expect it to last 3 years)
Patent covers liquid storage - preferred , but also cover for freeze dried stable storage too .
According to an exemplary embodiment of the present invention, a liquid antibody formulation can be made by taking the anti-CLEVER-1 antibody in liquid form and buffer exchanging it into the desired formulation. There is no lyophilization step in this embodiment. The drug substance in the final buffer is concentrated to a desired concentration. Excipients, such as trehalose dihydrate and polysorbate 20 are added to the solution and it is diluted using the appropriate buffer to final protein concentration. The final formulated drug substance is filtered using 0.22 μm filters and filled into a final container (e.g. glass vials).
According to an embodiment of the present invention, a formulation can also be a lyophilized formulation, i.e. lyophilisate. The term “lyophilisate” refers to the product of lyophilisation. The term “lyophilize” with regard to pharmaceutical formulations of the invention is intended to refer to freeze drying of a solution of the formulation. Lyophilized formulations of therapeutic proteins may provide advantages, such as better chemical stability. A lyophilized formulation may also be reconstituted at different concentrations depending on clinical factors, such as route of administration or dosing. The term “reconstitution” refers to dissolution of the lyophilisate for achieving an aqueous solution.
It has been observed that pharmaceutical formulation according to the present invention stabilize anti-CLEVER-1 antibodies or antigen binding fragment(s) thereof against degradation during storage. According to an embodiment of the present invention a formulation comprising an anti-CLEVER-1 antibody or antigen binding fragment(s) thereof has storage stability at 2-8° C. A good stability at high concentrations, even at concentrations of 100 mg/ml of anti-CLEVER-1 antibodies or antigen binding fragment(s) thereof can be achieved. A “stable” pharmaceutical formulation according to the present invention is a pharmaceutical formulation comprising an anti-CLEVER-1 antibody or antigen binding fragment(s) thereof with no significant changes observed at a refrigerated temperature 2-8° C. for at least 3 months. The formulation according to the invention has been observed to be storage stable at temperature of 2-8° C. for at least 18 months or 24 months. A pharmaceutical formulation is considered to be storage stable at temperature of 2-8° C. for even at least 30 months and even a period of 36 months.
Joining yesterday , I thought I was a bit late to the party , having never even come across this company until a couple of days ago .
I guess you can only keep so many companies on your radar .
Reading into the details - the potential here is massive .
A lot of companies can talk the talk , but once data starts coming in that is statistically significant and commercially marketable - into an area with a real unmet need , thats when the big money starts coming in .
Fingers crossed .